Access Mostly Preserved

The FDA completes the delayed review in March 2027 and finds no basis for major restrictions, emphasizing the existing safety record and postmarketing surveillance. This is plausible because courts have historically deferred to FDA expertise and the agency may prefer a defensible administrative record over a sweeping reversal.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.